Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer
NCT00881361 · View on ClinicalTrials.gov ↗
Study Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase II trial is studying surgery to remove the sentinel lymph node and axillary lymph nodes after chemotherapy in treating women with stage II, stage IIIA, or stage IIIB breast cancer.
Conditions Studied
Interventions
- PROCEDURE therapeutic conventional surgery
- DRUG systemic chemotherapy
- PROCEDURE axillary lymph node dissection
- PROCEDURE neoadjuvant therapy
- PROCEDURE sentinel lymph node biopsy
Study Locations (20)
California
- East Bay Radiation Oncology Center — Castro Valley
- Valley Medical Oncology Consultants - Castro Valley — Castro Valley
- Cancer Care Center at John Muir Health - Concord Campus — Concord
- City of Hope Comprehensive Cancer Center — Duarte
- Valley Medical Oncology — Fremont
- Todd Cancer Institute at Long Beach Memorial Medical Center — Long Beach
- USC/Norris Comprehensive Cancer Center and Hospital — Los Angeles
- Contra Costa Regional Medical Center — Martinez
- Community Hospital of the Monterey Peninsula Comprehensive Cancer Center — Monterey
- Camino Medical Group - Treatment Center — Mountain View
- El Camino Hospital Cancer Center — Mountain View
- Highland General Hospital — Oakland
- Bay Area Breast Surgeons, Incorporated — Oakland
- CCOP - Bay Area Tumor Institute — Oakland
- Larry G Strieff MD Medical Corporation — Oakland
- Tom K Lee, Incorporated — Oakland
- Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center — Orange
Alabama
- University of South Alabama Mitchell Cancer Institute — Mobile
Alaska
- Providence Cancer Center — Anchorage
Arkansas
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences — Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 756 participants |
| Start Date | 2009-07 |
| Est. Completion | 2023-04-15 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00881361
The ClinicalTrials.gov registry entry for NCT00881361 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 756 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 147 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions — of which therapeutic conventional surgery is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00881361 reports 20 study locations spanning 4 distinct geographic areas — top geographies include California, Alabama, Alaska. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00881361 about?
NCT00881361 is a clinical study titled "Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer". RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This...
What is the current status of trial NCT00881361?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 756 participants. The study started on 2009-07. Estimated completion is 2023-04-15.
What conditions does trial NCT00881361 study?
This clinical trial studies the following conditions: Breast Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00881361?
The interventions under investigation include: therapeutic conventional surgery (PROCEDURE), systemic chemotherapy (DRUG), axillary lymph node dissection (PROCEDURE), neoadjuvant therapy (PROCEDURE), sentinel lymph node biopsy (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00881361?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 147 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00881361 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.